TY - JOUR
T1 - Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines :
T2 - a critical appraisal using AGREE II and AGREE-REX tool
AU - Santero, Marilina
AU - de Mas, Júlia
AU - Rifà, Berta
AU - Clavero, Inés
AU - Rexach, Irene
AU - Bonfill, X. (Xavier)
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2024/1
Y1 - 2024/1
N2 - Background: The Spanish Society of Medical Oncology (SEOM) has provided open-access guidelines for cancer since 2014. However, no independent assessment of their quality has been conducted to date. This study aimed to critically evaluate the quality of SEOM guidelines on cancer treatment. Methods: Appraisal of Guidelines for Research and Evaluation II (AGREE II) and AGREE-REX tool was used to evaluate the qualities of the guidelines. Results: We assessed 33 guidelines, with 84.8% rated as “high quality”. The highest median standardized scores (96.3) were observed in the domain “clarity of presentation”, whereas “applicability” was distinctively low (31.4), with only one guideline scoring above 60%. SEOM guidelines did not include the views and preferences of the target population, nor did specify updating methods. Conclusions: Although developed with acceptable methodological rigor, SEOM guidelines could be improved in the future, particularly in terms of clinical applicability and patient perspectives.
AB - Background: The Spanish Society of Medical Oncology (SEOM) has provided open-access guidelines for cancer since 2014. However, no independent assessment of their quality has been conducted to date. This study aimed to critically evaluate the quality of SEOM guidelines on cancer treatment. Methods: Appraisal of Guidelines for Research and Evaluation II (AGREE II) and AGREE-REX tool was used to evaluate the qualities of the guidelines. Results: We assessed 33 guidelines, with 84.8% rated as “high quality”. The highest median standardized scores (96.3) were observed in the domain “clarity of presentation”, whereas “applicability” was distinctively low (31.4), with only one guideline scoring above 60%. SEOM guidelines did not include the views and preferences of the target population, nor did specify updating methods. Conclusions: Although developed with acceptable methodological rigor, SEOM guidelines could be improved in the future, particularly in terms of clinical applicability and patient perspectives.
KW - Cancer
KW - Evidence-based medicine
KW - Medical oncology
KW - Practice guidelines as topic
KW - Quality assessment
KW - Review
UR - https://www.scopus.com/pages/publications/85163675813
UR - https://www.mendeley.com/catalogue/6b71f65f-3b8e-3e59-b40d-cb9ed672029a/
U2 - 10.1007/s12094-023-03219-0
DO - 10.1007/s12094-023-03219-0
M3 - Article
C2 - 37368198
SN - 1699-3055
VL - 26
SP - 85
EP - 97
JO - Clinical & Translational Oncology
JF - Clinical & Translational Oncology
IS - 1
ER -